Patents by Inventor Mihue JANG

Mihue JANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240151728
    Abstract: The disclosure relates to a fluorescence resonance energy transfer (FRET)-based biosensor for sensing chimeric antigen receptor (CAR) activity and use thereof, and in particular, to a FRET-based biosensor, which simultaneously detects binding of an antigen-binding receptor domain to a cancer antigen and consequent activation of T cells, and a method of screening for CAR activity in a live cell by using the FRET-based biosensor.
    Type: Application
    Filed: October 16, 2023
    Publication date: May 9, 2024
    Applicants: Korea Institute of Science and Technology, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Jihye SEONG, Mihue Jang, Haenim Lee, Hyejin Yoo, Chang-Han Lee, Jiyun Jeong, Hang-Rae Kim, Soojin Lee
  • Patent number: 11649282
    Abstract: Provided are a genetically modified immunocyte expressing a chimeric antigen receptor (CAR) comprising an antigen binding domain specifically binding to cancer cells and/or expressing TRAIL, a composition for preventing or treating cancer, the composition comprising the immunocytes, a cell therapeutic agent, a method of providing information for cancer diagnosis, and a method of preparing the genetically modified immunocyte.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: May 16, 2023
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
    Inventors: Mihue Jang, Eunsung Jun, Anna Ju
  • Publication number: 20220243186
    Abstract: Provided are a fusion protein used in a CRISPR/Cas system, and a complex including the same and use thereof. Since the gene editing complex including the fusion protein of the present disclosure includes an NKG2D ligand capable of binding to NKG2D expressed on the membrane of natural killer cells, it may be specifically delivered to NKG2D receptor-expressing cells or natural killer cells. Since it may be effectively delivered into the cells through endocytosis of NKG2D without a carrier, a target gene or a target DNA of NKG2D receptor-expressing cells or natural killer cells may be manipulated using the complex.
    Type: Application
    Filed: December 7, 2021
    Publication date: August 4, 2022
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Mihue JANG, Junghee KIM, Sang Chul SHIN, Young Eun LEE, Han-Na YOON
  • Publication number: 20210371515
    Abstract: Provided are a genetically modified immunocyte expressing a chimeric antigen receptor (CAR) comprising an antigen binding domain specifically binding to cancer cells and/or expressing TRAIL, a composition for preventing or treating cancer, the composition comprising the immunocytes, a cell therapeutic agent, a method of providing information for cancer diagnosis, and a method of preparing the genetically modified immunocyte.
    Type: Application
    Filed: March 10, 2020
    Publication date: December 2, 2021
    Applicants: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
    Inventors: Mihue JANG, Eunsung JUN, Anna JU
  • Patent number: 10266820
    Abstract: A RNA/DNA nanoparticle for delivering siRNA where a RNA transcript including at least one hairpin structure hybridizes DNA-cholesterol conjugate and folate-DNA conjugate including a complementary sequence to the RNA transcript, and a composition including the RNA/DNA nanoparticle is provided. More specifically, because various siRNA used for different applications can be contained in the RNA/DNA nanoparticle for delivering siRNA at a high loading efficiency, and has stability to the outer attacks such as nuclease degradation. The RNA/DNA nanoparticle siRNA can be prepared by self-assembly without using polycationic agent which is harmful agent for body. The folate targeting to various cancer cells can accumulate the nanoparticle selectively on target cancer cell after intravenous injection, and make excellent gene-silencing effect inside the cancer tissue, thereby being used as a good agent for treating cancers.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: April 23, 2019
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyung Jun Ahn, Ick Chan Kwon, Mihue Jang, Jong Hwan Kim
  • Publication number: 20160208245
    Abstract: A RNA/DNA nanoparticle for delivering siRNA where a RNA transcript including at least one hairpin structure hybridizes DNA-cholesterol conjugate and folate-DNA conjugate including a complementary sequence to the RNA transcript, and a composition including the RNA/DNA nanoparticle is provided. More specifically, because various siRNA used for different applications can be contained in the RNA/DNA nanoparticle for delivering siRNA at a high loading efficiency, and has stability to the outer attacks such as nuclease degradation. The RNA/DNA nanoparticle siRNA can be prepared by self-assembly without using polycationic agent which is harmful agent for body. The folate targeting to various cancer cells can accumulate the nanoparticle selectively on target cancer cell after intravenous injection, and make excellent gene-silencing effect inside the cancer tissue, thereby being used as a good agent for treating cancers.
    Type: Application
    Filed: June 29, 2015
    Publication date: July 21, 2016
    Inventors: Hyung Jun AHN, Ick Chan KWON, Mihue JANG, Jong Hwan KIM